Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Growth Hormone Treatment in Adult Patients With Chronic Kidney Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT00184652
First received: September 13, 2005
Last updated: January 23, 2017
Last verified: January 2017

September 13, 2005
January 23, 2017
April 2003
September 2005   (Final data collection date for primary outcome measure)
Change in surrogate markers of nutrition [ Time Frame: After 6 months treatment ]
Change in surrogate markers of nutrition after 6 months treatment
Complete list of historical versions of study NCT00184652 on ClinicalTrials.gov Archive Site
  • Quality of Life
  • Other markers of nutrition
Same as current
Not Provided
Not Provided
 
Growth Hormone Treatment in Adult Patients With Chronic Kidney Disease
The Effect of Norditropin® on Nutritional Status in Adult Patients in Chronic Haemodialysis
This trial is conducted in Asia, Europe, and Middle East. Adult patients with chronic kidney disease are treated with growth hormone to assess effect on nutritional status.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator
Primary Purpose: Treatment
  • Chronic Kidney Disease
  • End-Stage Renal Disease
Drug: somatropin
Not Provided
Feldt-Rasmussen B, Lange M, Sulowicz W, Gafter U, Lai KN, Wiedemann J, Christiansen JS, El Nahas M; APCD Study Group.. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. J Am Soc Nephrol. 2007 Jul;18(7):2161-71. Epub 2007 Jun 6.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
140
September 2005
September 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • ESRD patients

Exclusion Criteria:

  • Diabetes Mellitus
  • Severe and Malignant diseases
  • Patients in Intensive Care Units
Sexes Eligible for Study: All
18 Years to 99 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Denmark,   Germany,   Hong Kong,   Israel,   Poland,   Singapore,   Sweden,   Switzerland,   United Kingdom
China,   Czech Republic,   France
 
NCT00184652
NN1606-1442
No
Not Provided
Not Provided
Not Provided
Novo Nordisk A/S
Novo Nordisk A/S
Not Provided
Study Director: Global Clinical Registry (GCR 1452) Novo Nordisk A/S
Novo Nordisk A/S
January 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP